Literature DB >> 20626406

Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Matteo Cesari1, Marco Pahor, Raffaele Antonelli Incalzi.   

Abstract

INTRODUCTION: The close relationship existing between aging and thrombosis has growingly been studied in this last decade. The age-related development of a prothrombotic imbalance in the fibrinolysis homeostasis has been hypothesized as the basis of this increased cardiovascular and cerebrovascular risk. Fibrinolysis is the result of the interactions among multiple plasminogen activators and inhibitors constituting the enzymatic cascade, and ultimately leading to the degradation of fibrin. The plasminogen activator system plays a key role in a wide range of physiological and pathological processes.
METHODS: Narrative review.
RESULTS: Plasminogen activator inhibitor-1 (PAI-1) is a member of the superfamily of serine-protease inhibitors (or serpins), and the principal inhibitor of both the tissue-type and the urokinase-type plasminogen activator, the two plasminogen activators able to activate plasminogen. Current evidence describing the central role played by PAI-1 in a number of age-related subclinical (i.e., inflammation, atherosclerosis, insulin resistance) and clinical (i.e., obesity, comorbidities, Werner syndrome) conditions is presented.
CONCLUSIONS: Despite some controversial and unclear issues, PAI-1 represents an extremely promising marker that may become a biological parameter to be progressively considered in the prognostic evaluation, in the disease monitoring, and as treatment target of age-related conditions in the future.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626406      PMCID: PMC2958211          DOI: 10.1111/j.1755-5922.2010.00171.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  280 in total

1.  Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture.

Authors:  T Skurk; Y M Lee; H Hauner
Journal:  Hypertension       Date:  2001-05       Impact factor: 10.190

2.  Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study.

Authors:  Ann Marie McNeill; Ronit Katz; Cynthia J Girman; Wayne D Rosamond; Lynne E Wagenknecht; Joshua I Barzilay; Russell P Tracy; Peter J Savage; Sharon A Jackson
Journal:  J Am Geriatr Soc       Date:  2006-09       Impact factor: 5.562

3.  The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.

Authors:  E K Kruithof; J C Mestries; M P Gascon; A Ythier
Journal:  Thromb Haemost       Date:  1997-05       Impact factor: 5.249

Review 4.  Vascular thrombosis in type II diabetes mellitus.

Authors:  J A Colwell
Journal:  Diabetes       Date:  1993-01       Impact factor: 9.461

5.  Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors.

Authors:  T K Nordt; K Kornas; K Peter; S Fujii; B E Sobel; W Kübler; C Bode
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

Review 6.  The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.

Authors:  R W Stephens; N Brünner; F Jänicke; M Schmitt
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

7.  The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study.

Authors:  Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-10       Impact factor: 6.053

8.  Effects of electric footshock and water immersion restraint stresses on fibrinolytic parameters in the plasma of rats.

Authors:  Y Takada; T Urano; H Takahashi; N Nagai; A Takada
Journal:  Thromb Res       Date:  1998-02-01       Impact factor: 3.944

9.  Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study.

Authors:  Stefano Volpato; Marco Pahor; Luigi Ferrucci; Eleanor M Simonsick; Jack M Guralnik; Stephen B Kritchevsky; Renato Fellin; Tamara B Harris
Journal:  Circulation       Date:  2004-02-10       Impact factor: 29.690

10.  Increased expression of plasminogen activator inhibitor-1 by mediators of the acute phase response: a potential progenitor of vasculopathy in hypertensives.

Authors:  Jie Dong; Satoshi Fujii; Daisuke Goto; Tomoo Furumoto; Takeaki Kaneko; Tarkikuz A Zaman; Yukihito Nakai; Tetsuya Mishima; Shogo Imagawa; Akira Kitabatake
Journal:  Hypertens Res       Date:  2003-09       Impact factor: 3.872

View more
  138 in total

1.  Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model.

Authors:  Paul D DiMusto; Guanyi Lu; Abhijit Ghosh; Karen J Roelofs; Gang Su; Yunge Zhao; Christine L Lau; Omar Sadiq; Brendan McEvoy; Adriana Laser; Jose A Diaz; Thomas W Wakefield; Peter K Henke; Jonathan L Eliason; Gilbert R Upchurch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

Review 2.  Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

Authors:  Anna Tjärnlund-Wolf; Helen Brogren; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2012-08-09       Impact factor: 7.914

3.  Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis.

Authors:  Wen-Tan Huang; Hasina Akhter; Chunsun Jiang; Mark MacEwen; Qiang Ding; Veena Antony; Victor John Thannickal; Rui-Ming Liu
Journal:  Exp Gerontol       Date:  2014-11-28       Impact factor: 4.032

4.  The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.

Authors:  Penny M Kris-Etherton; Paul W Stewart; Henry N Ginsberg; Russell P Tracy; Michael Lefevre; Patricia J Elmer; Lars Berglund; Abby G Ershow; Thomas A Pearson; Rajasekhar Ramakrishnan; Stephen F Holleran; Barbara H Dennis; Catherine M Champagne; Wahida Karmally
Journal:  J Nutr       Date:  2020-08-01       Impact factor: 4.798

Review 5.  Fibrinolysis as a Target to Enhance Fracture Healing.

Authors:  Regis J O'Keefe
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

Review 6.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

7.  Protective effect of curcumin on pulmonary and cardiovascular effects induced by repeated exposure to diesel exhaust particles in mice.

Authors:  Abderrahim Nemmar; Deepa Subramaniyan; Badreldin H Ali
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

8.  Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Authors:  Ola Fjellström; Johanna Deinum; Tove Sjögren; Carina Johansson; Stefan Geschwindner; Viveca Nerme; Anne Legnehed; Jane McPheat; Karolina Olsson; Cristian Bodin; Amalia Paunovic; David Gustafsson
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

9.  Association of markers of hemostasis with death in HIV-infected women.

Authors:  Elizabeth Kiefer; Donald R Hoover; Qiuhu Shi; Mark H Kuniholm; Michael Augenbraun; Mardge H Cohen; Elizabeth T Golub; Robert C Kaplan; Chenglong Liu; Marek Nowicki; Phyllis C Tien; Russell P Tracy; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

10.  Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.

Authors:  Lihu Gong; Min Liu; Tu Zeng; Xiaoli Shi; Cai Yuan; Peter A Andreasen; Mingdong Huang
Journal:  J Biol Chem       Date:  2015-08-31       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.